Suggestions
Stephane Berthier
U.S. General Manager at Atara Biotherapeutics
Stephane Berthier is an executive with strong scientific and business qualifications in the biopharmaceutical industry.2 He joined Atara Biotherapeutics as Vice President and U.S. General Manager in August 2021.8 Prior to this role, Berthier worked at SymBio Pharma USA, Inc., where he was involved in leadership and finance.45 He has experience in cell and gene therapy manufacturing and commercialization.6 Berthier ended his time with Atara Biotherapeutics in July 2023, reflecting on his experience in bringing the first allogeneic T cell therapy to patients.3 Currently, he is the Founder & CEO at SDK Therapeutics.5
Education and Early Career
Berthier holds a Bachelor's degree and a Master's degree in Accounting and Finance from Université Jean Moulin (Lyon III).1
Professional Experience
- Founder & CEO at SDK Therapeutics (Current position)5
- Vice President and U.S. General Manager at Atara Biotherapeutics (August 2021 - July 2023)38
- Leadership role at SymBio Pharma USA, Inc. (prior to Atara Biotherapeutics)45
Berthier has expertise in clinical operations, having sought driven individuals to lead global clinical operations teams.7 His experience spans various aspects of the biopharmaceutical industry, including leadership, finance, and project management.45
Highlights
Following the acquisition of the exclusive right to develop and commercialize Arsenic Trioxide Oral Solution for North America and Europe, it was great to connect in person and kick off our collaboration with Patrick Wong from Jacobson Pharma Group, and Professor Kwong and Doctor Harry Gill from the The University of Hong Kong. Arsenic Trioxide Oral Solution has the potential to become the new standard of care in acute promyelocytic leukemia by addressing the significant treatment burden associated with the current IV formulation used in North America and Europe. We plan to leverage the available clinical evidence generated over many years by the University of Hong Kong to achieving our goal of rapidly bringing this oral treatment to patients in North America and Europe. We look forward to engaging with FDA and European Medicines Agency in the second half of 2024 to align on the design of an applicable registration trial. #SDKTx #SDK #APL #AML #Leukemia #EHA #EHA2024 #Treatmentburden #Hematology https://lnkd.in/e6cSMyX6
